BioLine Rx (BioLine Rx) Other Stockholders Equity : $1.41 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Other Stockholders Equity?

BioLine Rx's Other Stockholders Equity for the quarter that ended in Dec. 2023 was $1.41 Mil.

BioLine Rx's quarterly Other Stockholders Equity increased from Jun. 2023 ($1.41 Mil) to Sep. 2023 ($1.41 Mil) but then declined from Sep. 2023 ($1.41 Mil) to Dec. 2023 ($1.41 Mil).

BioLine Rx's annual Other Stockholders Equity increased from Dec. 2021 ($0.98 Mil) to Dec. 2022 ($1.41 Mil) but then declined from Dec. 2022 ($1.41 Mil) to Dec. 2023 ($1.41 Mil).

BioLine Rx Other Stockholders Equity Historical Data

The historical data trend for BioLine Rx's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Other Stockholders Equity Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

0.98

1.41

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Stockholders Equity	Get a 7-Day Free Trial															1.41	1.41	1.41	1.41	1.41

BioLine Rx Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

BioLine Rx Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.